Chikungunya Study

Age range: 18-45 years of age

Study criteria: Healthy adults who have not visited or lived longer than a month in locations known to have local chikungunya virus.

Contact email:

Contact Phone number: 404-727-4044

Study Description

We are studying a new vaccine that has been developed against chikungunya. This vaccine (MV-CHIK) has been created from a measles vaccine that has had chikungunya genes added to it. MVCHIK has been studied in one previous study where 36 young people received 2 doses of the vaccine. The vaccine was safe and the people who received the vaccine made antibodies to chikungunya virus. The purpose of this research study is to see whether MV-CHIK is safe and tolerable. It is also to see if MV-CHIK helps your body make antibodies and other immune cells. We will also look at the best dose and how it is to be given.

Who Can Participate?

Healthy adults 18 to 45 years of age

What is involved?

The study involves 7-8 clinic visits at Emory Children’s Center, which will range from 1-2 hours each. Subjects will receive two doses of the study vaccine, one on their first clinic visit and the next dose within 28 days.

This study is free. To say thank you, families will be compensated for their time and participation.